Blog
RSS FeedPosted by Michael Wonder on 11 Apr 2023
ICER publishes 2023 research protocol for assessing unsupported price increases on prescription drugs
11 April 2023 - Annual unsupported price increase report to be published on December 12. ...
Posted by Michael Wonder on 16 Mar 2023
ICER publishes white paper on using comparative effectiveness research to address prescription drug spending in California
16 March 2023 - State policy makers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 11 Mar 2023
Drug pricing throughout the product lifecycle: a work in progress
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
Posted by Michael Wonder on 17 Jan 2023
ICER publishes second annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
17 January 2023 - During ICER’s assessment, five payers revised policies for 11 medicines in ways that bring coverage into ...
Posted by Michael Wonder on 20 Oct 2022
ICER evaluates drug price increases in California
20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...
Posted by Michael Wonder on 17 Oct 2022
Can state prescription drug affordability boards address high cost drug prices?
11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...
Posted by Michael Wonder on 11 Oct 2022
New generation of weight loss medications offer promise — but at a price
11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...
Posted by Michael Wonder on 14 Apr 2022
ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs
14 April 2022 - Final assessment to be published on 6 December 2022. ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...
Posted by Michael Wonder on 03 Mar 2022
ICER to develop a California state unsupported price increase report funded by the California Health Care Foundation
3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through ...
Posted by Michael Wonder on 10 Feb 2022
A new way to contain unaffordable medication costs - exercising the Government’s existing rights
9 February 2022 - Existing laws could be used to help make many drugs more affordable. ...
Posted by Michael Wonder on 01 Dec 2021
ICER publishes first annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
1 December 2021 - Scope of assessment limited by gaps in availability of payer policies and inability to evaluate how policies ...
Posted by Michael Wonder on 16 Nov 2021
ICER identifies most significant 2020 US drug price hikes not supported by new clinical evidence
16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of ...